Novartis AG: Pasireotide Works Well in Phase III Acromegaly Trial

Basel, May 7, 2012 - Results of the largest Phase III study of acromegaly patients show the novel therapy pasireotide (SOM230) long-acting release (LAR), was significantly more effective at inducing f…
Read the full story: BioSpace.com Featured News